Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMOVA: Impact of Inmazeb on Ervebo Vaccine Response
NCT05202288Phase 2Not yet recruiting
- Sponsor
- ANRS
- Start
- Jan 2027
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of REGN-EB3 in Ebola virus disease (EVD), sponsored by ANRS. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
REGN-EB3
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT05202288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05202288.